For validation, we employed an integrative analysis strategy on a dataset comprising 27 tumor samples and 13 normal samples obtained from 19 patients with CRC undergoing neoadjuvant PD‐1 blockade therapy. This evidence concerns the gene PDCD1 and neoplasm.